Rischin, Danny; Harrington, Kevin J; Greil, Richard; Soulieres, Denis; Tahara, Makoto; Castro Junior, Gilberto de Castro 
; Psyrri, Amanda; Brana, Irene; Neupane, Prakash; Bratland, Ase
Fonte: Oral oncology. Unidade: FM
Assuntos: RECIDIVA LOCAL DE NEOPLASIA, NEOPLASIAS DE CABEÇA E PESCOÇO, RECIDIVA LOCAL DE NEOPLASIA, ENSAIO CLÍNICO, QUIMIOTERAPIA, IMUNOTERAPIA, CARCINOMA DE CÉLULAS ESCAMOSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RISCHIN, Danny et al. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: health-related quality-of-life results from KEYNOTE-048. Oral oncology, v. 128, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.oraloncology.2022.105815. Acesso em: 06 nov. 2024.APA
Rischin, D., Harrington, K. J., Greil, R., Soulieres, D., Tahara, M., Castro Junior, G. de C., et al. (2022). Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: health-related quality-of-life results from KEYNOTE-048. Oral oncology, 128. doi:10.1016/j.oraloncology.2022.105815NLM
Rischin D, Harrington KJ, Greil R, Soulieres D, Tahara M, Castro Junior G de C, Psyrri A, Brana I, Neupane P, Bratland A. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: health-related quality-of-life results from KEYNOTE-048 [Internet]. Oral oncology. 2022 ; 128[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/j.oraloncology.2022.105815Vancouver
Rischin D, Harrington KJ, Greil R, Soulieres D, Tahara M, Castro Junior G de C, Psyrri A, Brana I, Neupane P, Bratland A. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: health-related quality-of-life results from KEYNOTE-048 [Internet]. Oral oncology. 2022 ; 128[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/j.oraloncology.2022.105815
